New research has found that people with narcolepsy type 1 exhibit patterns of slow brain pulsations that resemble those seen in healthy sleep. The findings, published in PNAS, suggest that orexin—a ...
DUBLIN, Sept. 7, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 ...
H.C. Wainwright analyst Douglas Tsao keeps a Neutral rating on Alkermes (ALKS) with a $46 price target after the company presented detailed Phase 2 data from the Vibrance-1 study after previously ...
Researchers evaluated the relationship between narcolepsy and risk for cardiovascular disease when accounting for stimulant use.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback